Printer Friendly

CENTOCOR ACQUIRES MERCIA DIAGNOSTICS

 CENTOCOR ACQUIRES MERCIA DIAGNOSTICS
 MALVERN, Pa., Feb. 4 /PRNewswire/ -- Centocor, Inc. (NASDAQ: CNTO)


today announced the acquisition of Mercia Diagnostics Limited of Guildford, Surrey, U.K.
 Mercia, founded in 1984, develops, manufactures, and markets diagnostic products for infectious disease.
 "With this acquisition, our Centocor Diagnostics Division moves into the rapidly expanding field of infectious diseases, adding to its already well-established position in cancer diagnostics," said Hubert J.P. Schoemaker, chairman and chief executive officer of Centocor.
 During 1991, infectious disease products accounted for approximately 19 percent of the $8 billion worldwide in vitro diagnostics market. Over the next five years, this area is expected to grow at an average annual rate of nearly 20 percent, making it one of the fastest growing segments in the in vitro diagnostics field.
 In addition to new product opportunities, Mercia provides Centocor Diagnostics with a European manufacturing base and a strategic link with Centocor's pharmaceutical business, led by HA-1A, a human monoclonal antibody for the treatment of septic shock and gram negative bacterial infections of the bloodstream.
 "This move was a natural evolution for both companies," said David P.


Holveck, president of Centocor Diagnostics, a division of Centocor. "The combination of Mercia technology, market opportunity, and Centocor Diagnostics' worldwide distribution strength make this a formidable union."
 Centocor, based in Malvern, develops, manufactures, and markets diagnostic and therapeutic products for human health care. Centocor's products are based on monoclonal antibody technology and are primarily intended for use in infectious, cardiovascular, and autoimmune diseases and cancer.
 /delval/
 -0- 2/4/92
 /CONTACT: Richard Koenig of Centocor, 215-651-6122/
 (CNTO) CO: Centocor, Inc.; Mercia Diagnostics Limited ST: Pennsylvania IN: MTC SU: TNM


CC -- PH026 -- 6711 02/04/92 12:44 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 4, 1992
Words:283
Previous Article:ADVANCED MAGNETICS ANNOUNCES FILING OF INVESTIGATIONAL NEW DRUG APPLICATION
Next Article:WASHINGTON POST COMPANY REPORTS FOURTH QUARTER AND YEAR END RESULTS
Topics:


Related Articles
CENTOCOR EXERCISES CPII PURCHASE OPTION
CENTOCOR TO EXTEND TOCOR II OFFER
CENTOCOR TO HOLD CONFERENCE CALL TO DISCUSS 4TH QUARTER 1994 RESULTS
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL FOR CENTOCOR'S MYOSCINT
CENTOCOR COMPLETES PUBLIC OFFERING OF 4,025,000 SHARES OF COMMON STOCK AND SCHEDULES REDEMPTION OF 7-1/4% CONVERTIBLE SUBORDINATED NOTES
CENTOCOR REPORTS SECOND QUARTER 1996 FINANCIAL RESULTS
Centocor Reports First Quarter Financial Results; Second Consecutive Profitable Quarter Product Sales Up 107% From Q1 1996
Centocor Announces Initial Public Offering of Class A Common Stock Of its Subsidiary, Centocor Diagnostics, Inc.
Centocor Reaches Agreement to Sell Oncology Diagnostics Business.
Fujirebio Diagnostics Signs Agreement With North American Distributor.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters